It's really not that hard to find for someone of adequate skill.
Below is a systematic review of oncolytic viruses from 2020, which includes 86 clinical trials - 60, of which, are phase 1. Gee, I wonder why there aren't many P2s relative to P1s. Imagine doubling and tripling down on a product joining a loooong list of failures when you could have made bank like management and Fong did.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589713/
There have been 8 phase II trials investigating Bisantrene as a single agent at a 250 mg/m2 7-day regimen, with an average weighted CR rate of 50.7%. I've attached the 7 PDFs that are available with the other paper quoted in three of the papers.
Spadea 1993_P2 Bisantrene in relapsed refractory AML.pdf
Canaai 2020_P2 AML.pdf
Bezwoda 1989_Bisantrene in ANLL.pdf
Fenaux 1991_P2 Bisantrene as salvage Tx.pdf
Isnard 1987_P2 bisantrene in relapsing or refractory leukemia.pdf
Marty 1984_Bisantrene P2 in ANLL0001.pdf
Tosi 1989_P2 bisantrene in ANLL.pdf
Here is how that data compares to approved therapies in the same patient populations. Note: Bisantrene is a first-in-class CPACS drug that modulates m6A levels through the inhibition of FTO, which is also a first-in-class. The clinical competitors are 0 as are the commercial competitors.
Here is a P1 trial of Bisantrene that you should probably look at. Have you ever thought you don't understand Bisantrene because you don't know what good looks like? 35% ORR in this P1 is the same response rate quoted on the FDA label for Doxorubicin![]()
Marty 1985_ANLL (AML) P1.pdf
Now, show me a cardioprotective anti-cancer agent.
- Forums
- ASX - By Stock
- Cardioprotection thread
It's really not that hard to find for someone of adequate skill....
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M |
Open | High | Low | Value | Volume |
$1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 92 | $1.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.87 | 3472 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5300 | 1.810 |
1 | 8722 | 1.800 |
1 | 1059 | 1.790 |
4 | 10695 | 1.750 |
2 | 8147 | 1.730 |
Price($) | Vol. | No. |
---|---|---|
1.865 | 3472 | 1 |
1.880 | 2500 | 1 |
1.940 | 5148 | 2 |
1.945 | 3014 | 1 |
1.950 | 12000 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |